Previous Grant Recipients
Research Grant Awards
- Myotonic: Support for research capacity development and advocacy support 2015-2017
- Stanford University, Primary Investigator John Day, M.D., Ph.D.: Myotonic Dystrophy Clinical Research Network Multicenter Study of Natural History and Genetic Modifiers in Myotonic Dystrophy Type 1
- University of Utah, Primary Investigator Nicholas Johnson, M.D.: Myotonic Dystrophy Clinical Research Network Multicenter Study of Natural History and Genetic Modifiers in Myotonic Dystrophy Type 1
- Ohio State University, Primary Investigator John Kissel, M.D.: Myotonic Dystrophy Clinical Research Network Multicenter Study of Natural History and Genetic Modifiers in Myotonic Dystrophy Type 1
- University of Kansas Medical Center, Primary Investigator Jeffrey Statland, M.D.: Myotonic Dystrophy Clinical Research Network Multicenter Study of Natural History and Genetic Modifiers in Myotonic Dystrophy Type 1
- University of Florida, Primary Investigator S.H. Siubramony, M.D.: Myotonic Dystrophy Clinical Research Network Multicenter Study of Natural History and Genetic Modifiers in Myotonic Dystrophy Type 1
- European Neuromuscular Centre, Primary Investigator Alexandra Breukel, Ph.D., Workshop Support - Myotonic Dystrophy - Developing a European Consortium for Care and Therapy
- University of Utah, Primary Investigator Nicholas Johnson, M.D.: Phase I Development and Validation of Screening Technology for Myotonic Dystrophy Population-Based Prevalence Study
Fellowship Awards
- Anwesha Banerjee, Ph.D., Emory University: Mechanism of CNS-associated behavioral dysfunction in novel mouse model of Myotonic Dystrophy Type 1
- Kaalak Reddy, Ph.D., The University of Florida: Pre-clinical investigations of small molecule-mediated targeting of toxic RNA production in DM2
- Ian DeVolder, Ph.D., University of Iowa, U.S.: Structural and Functional Connectivity in the Brains of Patients with Adult and Late Onset Myotonic Dystrophy Type 1 (DM1) - A Potential Biomarker for Disease Progression
- Melissa M. Dixon, Ph.D., University of Utah, U.S.: Evaluation of Functional Connectivity as a Brain Biomarker in Congenital Myotonic Dystrophy
- Benjamin Gallais, Ph.D., Universite de Sherbrooke, Canada: A 14-Year Longitudinal Study of Cognition and Central Nervous System Involvement in Adult and Late-Onset Phenotypes of Myotonic Dystrophy Type 1
- Ginny R. Morriss, Ph.D., Baylor University, U.S.: Mechanisms of Skeletal Muscle Wasting Caused by Expanded CUG Repeat RNA
- Laura Valentina Renna, Ph.D., IRCCS-Policlinico San Donato, Italy: A New Approach of Pathomolecular Mechanisms in Myotonic Dystrophy Insulin Resistance by Nutrigenomics
- Lukasz Sznajder, Ph.D., University of Florida, U.S.: Myotonic Dystrophy Type 2 - Mouse Models, Pathomechanism and Therapy
- Viachaslau Bernat, Ph.D., The Scripps Research Institute - Florida, US: Precise Lead Therapeutics for Myotonic Dystrophy via in cellulo Synthesis
- Ranjan Batra, Ph.D., University of California San Diego, U.S.: Studying Genome-Wide MBNL-RNA Structure Interactions in Neuronal Development and Myotonic Dystrophy
- Melissa Hinman, Ph.D., University of Oregon, U.S.: An Investigation of the Cellular and Microbial Etiologies of Gastrointestinal Pathologies in Myotonic Dystrophy Using the Zebrafish
- Ashish Rao, Baylor College of Medicine, U.S.: Tissue specific expression of expanded CUG repeat RNA to investigate the cardiac pathogenesis of myotonic dystrophy type 1
- Florent Porquet, University of Liege, Belgium.: CRISPRI-induced transcriptional silencing of DMPK as a therapeutic strategy against myotonic dystrophy type 1
- Curtis Nutter, Ph.D., University of Florida, U.S.: Congenital myotonic dystrophy: pathomechanism and therapeutic development
- Kiruphagaran Thangaraju, Ph.D., University of Florida, U.S.: Molecular characterization of RNA and RAN protein effects in DM2